Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“Five years later, in 2019, GlaxoSmithKline acquired Tesaro. In 2021, AnaptysBio's cancer drug Jemperli was approved. Five years after that, GSK spent $10.6B to acquire Nuvalent and their cancer portfolio. This year, Jemperli will generate more than $1B of revenue for GSK. An agreement requiring exclusivity, notification rights, and an 'optimal commercial return' may have made sense between AnaptysBio and Tesaro, but it may not fit GSK's effort to optimize a cancer portfolio in which it has invested tens of billions of dollars. GSK describes Jemperli as a proprietary immuno-oncology backbone being developed across several solid tumors and estimates more than £2B in peak-year sales potential. The size of the Nuvalent acquisition shows the scale of GSK's oncology ambitions. Using their own checkpoint inhibitor gives GSK greater control over trial design, development timing, and economics than relying on another company's drug. This suggests that Jemperli may be worth more to GSK as a strategic building block than their current sales alone imply. AnaptysBio is suing GSK for allegedly violating provisions governing notification, exclusivity, and commercial optimization. At the trial, it was disclosed that GSK had tried to buy AnaptysBio three times in the past year.” | NEUTRAL | Q2 2026 Aug 14, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
